Is topical nitric oxide and cryotherapy more effective than cryotherapy in the treatment of old world cutaneous leishmaniasis?

Journal of Dermatological Treatment

Volumn 23, Issue 2, 2012, Pages 131-135

  Jowkar, Farideh ^a   Dehghani, Farideh ^a   Jamshidzadeh, Akram ^b  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Cryotherapy; Leishmaniasis; Nitric oxide

Indexed keywords

NITRIC OXIDE; PLACEBO;

ADOLESCENT; ADULT; ARTICLE; BURNING SENSATION; CHILD; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; CONTROLLED STUDY; CRYOTHERAPY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; ERYTHEMA; FEMALE; HUMAN; IRAN; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SKIN IRRITATION; SKIN LEISHMANIASIS; SKIN MANIFESTATION; SKIN NODULE; SKIN PLAQUE; TOPICAL TREATMENT; TREATMENT RESPONSE; URBAN RURAL DIFFERENCE;

ADOLESCENT; ADULT; ANTIPARASITIC AGENTS; CHILD; COMBINED MODALITY THERAPY; CRYOTHERAPY; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LEISHMANIA MAJOR; LEISHMANIA TROPICA; LEISHMANIASIS, CUTANEOUS; MALE; MIDDLE AGED; NITRIC OXIDE; YOUNG ADULT;

EID: 84858205731     PISSN: 09546634     EISSN: 14711753     Source Type: Journal    
DOI: 10.3109/09546634.2010.495380     Document Type: Article

References (20)

1. Herwaldt BL. Leishmaniasis. Lancet. 1999;354(9185):1191-1199. (Pubitemid 29460458)
2. Fatima F, Khalid A, Nazar N, Abdalla M, Mohomed H, Toum AM, et al. In vitro assessment of anti-cutaneous leishmaniasis activity of some Sudanese plants. Türkiye Para-zitol Derg. 2005;29:3-6.
3. Abass K, Saad H, Abd-Elsayed AA. The first case of isolated facial cutaneous leishmaniasis in a Down syndrome infant: A case report and review of the literature. Cases J. 2009;2(1):13.
4. Von Stebut E. Cutaneous leishmania infection: Progress in pathogenesis research and experimental therapy. Exp Derma-tol. 2007;16(4):340-346. (Pubitemid 46394850)
5. Jaafari MR, Behravan J, Bodagh Abadi A, Ramezani M. Evaluation of leishmanicidal effect of Euphorbia myrsinites extract by in vitro antileishmanial assay using promastigote of Leishmania major. Iranian J Basic Med Sci. 2005;8:295-298.
6. Bryceson A. Therapy in man. In: Peters W, Killick-Kendrick R, editors. The leishmaniases. London: Elsevier; 1987. p. 847-869.
7. Garnier T, Croft SL. Topical treatment for cutaneous leish-maniasis. Curr Opin Investig Drugs. 2002;3:538-544.
8. Nathan C, Shiloh MU. Reactive oxygen and nitrogen intermediates in the relationship between mammalian hosts and microbial pathogens. Proc Natl Acad Sci USA. 2000;97: 8841-8848. (Pubitemid 30626635)
9. Mauël J, Ransijn A, Buchmüller-Rouiller Y. Killing of Leish-mania parasites in activated murine macrophages is based on an L-arginine-dependent process that produces nitrogen deri-vates. J Leukoc Biol. 1991;49:73-82.
10. Gradoni L, Ascenzi P. Nitric oxide and anti-protozoan chemotherapy. Parassitologia. 2004;46(1-2):101-103. (Pubitemid 40063857)
11. Holzmuller P, Sereno D, Cavaleyra M, Mangot I, Daulouede S, Vincendeau P, et al. Nitric oxide-mediated proteasome-dependent oligonucleosomal DNA fragmentation in Leishmania amazonensis amastigotes. Infect Immun. 2002;70(7):3727-3735. (Pubitemid 34666012)
12. Kröncke KD, Suschek CV. Adulterated effects of nitric oxide-generating donors. J Invest Dermatol. 2008;128:258-260.
13. Jowkar F, Jamshidzadeh A, Pakniyat S, Namazi MR. Efficacy of nitric oxide-liberating cream on pityriasis versicolor. J Dermatolog Treat. 2009;1:1-4.
14. Oliveira SH, Fonseca SG, Romão PR, Ferreira SH, Cunha FQ. Nitric oxide mediates the microbicidal activity of eosinophils. Mem Inst Oswaldo Cruz. 1997;92(suppl 2): 233-235.
15. Nahrevanian H, Najafzadeh M, Hajihosseini R, Nazem H, Farahmand M, Zamani Z. Anti-leishmanial effects of trinitro-glycerin in BALB/C mice infected with Leishmania major via nitric oxide pathway. Korean J Parasitol. 2009;47(2):109-115.
16. Nahrevanian H, Farahmand M, Aghighi Z, Assmar M, Amirkhani A. Pharmacological evaluation of anti-leishmanial activity by in vivo nitric oxide modulation in Balb/c mice infected with Leishmania major MRHO/IR/75/ER: An Iranian strain of cutaneous leishmaniasis. Exp Parasitol. 2007;116(3): 233-240. (Pubitemid 46709888)
17. Davidson RN, Yardley V, Croft SL, Konecny P, Benjamin N. A topical nitric oxide-generating therapy for cutaneous leishmaniasis. Trans R Soc Trop Med Hyg. 2000;94(3):319-322. (Pubitemid 30406570)
18. López-Jaramillo P, Ruano C, Rivera J, Terán E, Salazar-Irigoyen R, Esplugues JV, et al. Treatment of cutaneous leishmaniasis with nitric-oxide donor. Lancet. 1998; 351(9110):1176-1177. (Pubitemid 28171824)
19. Mosleh IM, Geith E, Natsheh L, Schönian G, Abotteen N, Kharabsheh S. Efficacy of a weekly cryotherapy regimen to treat Leishmania major cutaneous leishmaniasis. J Am Acad Dermatol. 2008;58(4):617-624.
20. Bassiouny A, El Meshad M, Talaat M, Kutty K, Metawaa B. Cryosurgery in cutaneous leishmaniasis. Br J Dermatol. 1982;107(4):467-474. (Pubitemid 12028402)